Multiple sclerosis and pregnancy in the 'treatment era'

Nature Reviews Neurology

Volumn 11, Issue 5, 2015, Pages 280-289

  Vukusic, Sandra ^a,b,c   Marignier, Romain ^a,b,c  

^a HÔPITAL NEUROLOGIQUE   (France)

^b LYON NEUROSCIENCE RESEARCH CENTER   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 IMMUNOGLOBULIN G ANTIBODY; CENTRAL NERVOUS SYSTEM AGENTS; DISEASE MODIFYING DRUG; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; NATALIZUMAB; RITUXIMAB; SEX HORMONE; UNCLASSIFIED DRUG;

BREAST FEEDING; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; EPIDURAL ANESTHESIA; FAMILY COUNSELING; FAMILY PLANNING; FEMALE FERTILITY; FETUS RISK; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY THERAPY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; PATIENT RISK; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PUERPERIUM; RELAPSE; REVIEW; RISK ASSESSMENT; SPINAL ANESTHESIA; CONTRAINDICATIONS; COUNSELING; FEMALE; INFERTILITY, FEMALE; MATERNAL CARE; NEUROMYELITIS OPTICA; OBSTETRIC ANALGESIA; PREGNANCY COMPLICATIONS; PRENATAL CARE; RISK FACTOR; SECONDARY PREVENTION;

ANALGESIA, EPIDURAL; ANALGESIA, OBSTETRICAL; BREAST FEEDING; COUNSELING; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFERTILITY, FEMALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; PRECONCEPTION CARE; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; REPRODUCTIVE TECHNIQUES, ASSISTED; RISK FACTORS; SECONDARY PREVENTION;

EID: 84929291966     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.53     Document Type: Review

References (70)

1. Confavreux, C., Hutchinson, M., Hours, M. M., Cortinovis-Tourniaire, P. & Moreau, T. Rate of pregnancy-related relapse in multiple sclerosis. N. Engl. J. Med. 339, 285-291 (1998).
2. Vukusic, S. et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127, 1353-1360 (2004).
3. Salemi, G. et al. The relapse rate of multiple sclerosis changes during pregnancy: a cohort study. Acta Neurol. Scand. 110, 23-26 (2004).
4. Portaccio, E. et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 77, 145-150 (2011).
5. Finkelsztejn, A., Brooks, J. B., Paschoal, F. M. & Fragoso, Y. D. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG 118, 790-797 (2011).
6. Hellwig, K., Haghikia, A., Rockhoff, M. & Gold, R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther. Adv. Neurol. Disord. 5, 247-253 (2012).
7. Hughes, S. E. et al. Predictors and dynamics of post-partum relapses in women with multiple sclerosis. Mult. Scler. 20, 739-746 (2014).
8. Saraste, M. H., Kurki, T. & Airas, L. M. Postpartum activation of multiple sclerosis: MRI imaging and immunological characterization of a case. Eur. J. Neurol. 13, 93-102 (2006).
9. Paavilainen, T. et al. Magnetic resonance imaging of the brain used to detect early post-partum activation of multiple sclerosis. Eur. J. Neurol. 14, 1216-1221 (2007).
10. Fragoso, Y. D. et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin. Neurol. Neurosurgery 115, 154-159 (2012).
11. D'hooghe, M. B., Nagels, G. & Uitdehaag, B. M. Long-term effects of childbirth in MS. J. Neurol. Neurosurg. Psychiatry 81, 38-41 (2010).
12. Miller, D. H., Fazekas, F., Montalban, X., Reingold, S. C. & Trojano, M. Pregnancy, sex and hormonal factors in multiple sclerosis. Mult. Scler. 20, 527-536 (2014).
13. Drake, E., Drake, M., Bird, J. & Russell, R. Obstetric regional blocks for women with multiple sclerosis: a survey of UK experience. Int. J. Obstet. Anesth. 15, 115-123 (2006).
14. Pasto, L. et al. for the MS Study Group of the Italian Neurological Society. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol. 12, 165-171 (2012).
15. Lu, E. et al. Obstetrical epidural and spinal anesthesia in multiple sclerosis. J. Neurol. 260, 2620-2628 (2013).
16. World Health Organization. Infant and young child nutrition. Global strategy on infant and young child feeding [online], http://apps.who.int/gb/archive/pdf-files/WHA55/ea5515.pdf?ua=1 (2002).
17. Langer-Gould, A. & Hellwig, K. One can prevent post-partum MS relapses by exclusive breastfeeding: yes. Mult. Scler. 19, 1567-1568 (2013).
18. Vukusic, S., Confavreux, C. One can prevent post-partum MS relapses by exclusive breastfeeding: no. Mult. Scler. 19, 1565-1566 (2013).
19. Hutchinson, M. One can prevent post-partum MS relapses by exclusive breast feeding: commentary. Mult. Scler. 19, 1569-1570 (2013).
20. Whitaker, J. N. Effects of pregnancy and delivery on disease activity in multiple sclerosis. N. Engl. J. Med. 339, 339-340 (1998).
21. Langer-Gould, A. et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch. Neurol. 66, 958-963 (2009).
22. Airas, L., Jalkanen, A., Alanen, A., Pirttila, T. & Marttila, R. J. Breastfeeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology 75, 474-476 (2010).
23. Neuteboom, R. F. & Hintzen, R. Q. Breastfeeding, postpartum and prepregnancy disease activity inmultiple sclerosis. Neurology 76, 1532 (2011).
24. Pakpoor, J. et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J. Neurol. 259, 2246-2248 (2012).
25. Kieseier, B. C. & Wiendl, H. Postpartum disease activity and breastfeeding in multiple sclerosis revisited. Neurology 75, 392-393 (2010).
26. Cavalla, P. et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol. Sci. 27, 231-239 (2006).
27. Hellwig, K. & Correale, J. Artificial reproduction techniques in multiple sclerosis. Clin. Immunol. 149, 219-224 (2013).
28. Laplaud, D. A., Leray, E., Barriere, P., Wiertlewski, S. & Moreau, T. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology 66, 1280-1281 (2006).
29. Hellwig, K. et al. Increased MS relapse rate during assisted reproduction technique. J. Neurol. 255, 592-593 (2008).
30. Hellwig, K., Schimrigk, S., Beste, C., Muller, T. & Gold, R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur. Neurol. 61, 65-68 (2009).
31. Michel, L. et al. on behalf of the Club Francophone de la Sclerose En Plaques (CFSEP). Increased risk of multiple sclerosis relapse after in vitro fertilization. J. Neurol. Neurosurg. Psychiatry 83, 796-802 (2012).
32. Correale, J., Farez, M. F. & Ysrraelit, M. C. Increase in multiple sclerosis activity after assisted reproduction technology. Ann. Neurol. 72, 682-694 (2012).
33. Food and Drug Administration, Department of Health and Human Services. C ontent and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling [online], http://www.fda.gov/ohrms/dockets/98fr/E8-11806.htm (2008).
34. European Medicines Agency. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. [online], http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003307.pdf (2005).
35. Haghikia, A. et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 71, 891-895 (2014).
36. Miller, D. H. et al. for the International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
37. O'Connor, P. W. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 76, 1858-1865 (2011).
38. Killestein, J. et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann. Neurol. 68, 392-395 (2010).
39. Kerbrat, A. et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J. Neurol. Sci. 308, 98-102 (2011).
40. Papeix, C., Depaz, R., Tourbah, A., Stankoff, B. & Lubetzki, C. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse. Mult. Scler. 17, 1520-1522 (2011).
41. Martinelli, V. et al. Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult. Scler. http://dx.doi.org/10.1177/1352458513492246.
42. Vukusic, S. et al. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Mult. Scler. http://dx.doi.org/10.1177/1352458514554056.
43. Sempere, A. P., Berenguer-Ruiz, L. & Feliu-Rey, E. Rebound of disease activity during pregnancy after withdrawal of fingolimod. Eur. J. Neurol. 20, e109-e110 (2013).
44. Park-Wyllie, L. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62, 385-392 (2000).
45. Carmichael, S. L. et al. for the National Birth Defects Prevention Study. Maternal corticosteroid use and orofacial clefts. Am. J. Obstet. Gynecol. 197, 585.e1-585.e7 (2007).
46. Hviid, A. & Molgaard-Nielsen, D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 183, 796-804 (2011).
47. Bjorn, A. M., Nielsen, R. B., Norgaard, M., Nohr, E. A. & Ehrenstein, V. Risk of miscarriage among users of corticosteroid hormones: a population-based nested case-control study. Clin. Epidemiol. 5, 287-294 (2013).
48. Achiron, A. et al. Effect of intravenous immunoglobulin treatment on pregnancy and post-partum related relapses in multiple sclerosis. J. Neurol. 251, 1133-1137 (2004).
49. Confavreux, C. Intravenous immunoglobulins, pregnancy and multiple sclerosis. J. Neurol. 251, 1138-1139 (2004).
50. Haas, J. & Hommes, O. R. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult. Scler. 13, 900-908 (2007).
51. Hellwig, K., Beste, C., Schimrigk, S. & Chan, A. Immunomodulation and postpartum relapses in patients with multiple sclerosis. Ther. Adv. Neurol. Disord. 2, 7-11 (2009).
52. Fragoso, Y. D. et al. Postpartum treatment with immunoglobulin does not prevent relapses of multiple sclerosis in the mother. Health Care Women Int. 3, 1-9 (2014).
53. De Sèze, J. et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult. Scler. 10, 596-597 (2004).
54. Sicotte, N. L. et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52, 421-428 (2002).
55. Vukusic, S. et al. The prevention of post-partum relapses with progestin and estradiol in multiple sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement. J. Neurol. Sci. 286, 114-118 (2009).
56. Cree, B. A. C. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult. Scler. 19, 835-843 (2013).
57. Wingerchuk, D. et al. The spectrum of neuromyelitis optica. Lancet Neurol. 6, 805-815 (2007).
58. Bourre, B. et al. Neuromyelitis optica and pregnancy. Neurology 78, 875-879 (2012).
59. Kim, W. et al. Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 78, 1264-1267 (2012).
60. Fragoso, Y. D. et al. Neuromyelitis optica and pregnancy. J. Neurol. 260, 2614-2619 (2013).
61. Sadana, N. et al. Anesthetic management of a parturient with neuromyelitis optica. Int. J. Obstet. Anesth. 21, 371-375 (2012).
62. Ritzenthaler, T. et al. First attack of Devic's neuromyelitis optica following endovascular treatment and rupture of brain arteriovenous malformation. Mult. Scler. 17, 895-896 (2011).
63. Saadoun, S. et al. Neuromyelitis optica IgG causes placental inflammation and fetal death. J. Immunol. 191, 2999-3005 (2013).
64. Asgari, N., Henriksen, T. B., Petersen, T., Lillevang, S. T. & Weinshenker, B. G. Pregnancy outcomes in a woman with neuromyelitis optica. Neurology 83, 1576-1577 (2014).
65. Kimbrough, D. J. et al. Treatment of neuromyelitis optica: review and recommendations. Mult. Scler. Relat. Disord. 1, 180-187 (2012).
66. Pellkofer, H. L. et al. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult. Scler. 15, 1006-1008 (2009).
67. Ringelstein, M. et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult. Scler. 19, 1544-1547 (2013).
68. Compston, A. & Coles, A. Multiple sclerosis. Lancet 359, 1221-1231 (2002).
69. Hale, T. W. et al. Transfer of interferon β-1a into human breastmilk. Breastfeed Med. 7, 123-125 (2012).
70. Multiple Sclerosis Trust UK. Pregnancy and parenthood fact sheet [online], http://www.mstrust.org.uk/downloads/pregnancy.pdf (2014).